Tesamorelin + CJC-1295 + Ipamorelin is a peptide combination that has attracted interest in research involving growth-hormone signaling, endocrine pathways, and metabolic biology. The three compounds are associated with growth-hormone-related mechanisms, but the scientific evidence for using them together is limited and should be distinguished from claims commonly made in online marketing. Tesamorelin is a growth hormone-releasing hormone analogue with established clinical research. In the United States, tesamorelin is approved for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Its approved labeling does not include general weight-loss treatment. CJC-1295 is an investigational GHRH-related peptide. Human research has examined its effects on growth hormone and IGF-1 levels, but clinical evidence remains limited. The FDA has identified potential safety concerns involving CJC-1295, including reported tachycardia and systemic vasodilatory reactions, as well as concerns related to peptide impurities and immunogenicity.
